Purdue Frederick’s Gentlax
This article was originally published in The Tan Sheet
Executive Summary
Marketing support for new bisacodyl USP 5 mg stimulant laxative includes FSI that dropped Dec. 8, cable and network TV ads, rebates, physician samples and direct mail, Purdue says. Ad agency is Della Femina Rothschild Jeary & Partners (New York). Purdue previously sold Gentlax granules containing senna but discontinued the product several years ago. Senna is a Category III ingredient under the OTC laxatives tentative final monograph; bisacodyl has been reclassified as Category I. Gentlax began shipping Nov. 1; packages of 20 and 100 tablets carry wholesaler prices of $2.96 and $12.25, respectively. Purdue, other companies are sponsoring carcinogenicity research on senna. Firm plans to submit data to FDA in March supporting Category I status for senna, which is found in Purdue's Senokot laxatives...
You may also be interested in...
Colace, Slow-Mag Buy Part Of Purdue Consumer Health Growth Plan
Purdue Pharma's acquisition of the Colace stool softener, Peri-Colace laxative capsule and Slow-Mag dietary supplement brands from Shire Pharmaceuticals Group is part of the firm's strategy to grow and diversify its consumer health business
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.